# data[].attributes.attachment_caption
A New Match for Menopausal Weight Gain: Ozempic

# data[].attributes.headline
Ozempic causing a change for women going through menapause

# data[].attributes.subject
Ozempic causing a change for women going through menapause

# data[].attributes.body
Many women including, Kimberly Smith, a 57 year old woman going through menopause, noticed a sufficient gain of weight after beginning menapause. This weight gain made her feel like she has no control over her life and body. This past April, she began using Ozempic and lost a total of 35 pounds.experts worry that these medications will have negative long term effects like loss of muscle mass and bone density which is is already common among meanapausal women.
- I think that Ozempic is a good short term weight loss substitute but I worry about the future of all these women

# data[].attributes.attachment_link.title
A New Match for Menopausal Weight Gain: Ozempic

# data[].attributes.attachment_link.description
Weight gain is one of the most common concerns among women going through menopause. New drugs could change that.

# data[].attributes.attachment_caption
Ozempic for weight loss: Does it work, and what do experts recommend?

# data[].attributes.body
Ozempic was originally used for adults with type 2 diabetes. Ozempic is a weekly injection that helps lower blood sugar by helping the pancreas make more insulin. It is not approved for weight loss but many physicians prescribe it to be used for weight loss. It mimics a naturally occurring hormone that tells your brain you are full.
- I think this drug is kind of scary and that it doesn’t seem to have a lot of research behind it.

# data[].attributes.attachment_link.title
Ozempic for weight loss: Does it work, and what do experts recommend?

# data[].attributes.attachment_link.description
A new trend has been getting a lot of attention: people using the diabetes drug Ozempic to lose weight. But is it safe and effective? Our health experts give their insights.

# data[].attributes.body
A women from New York that was not licensed to administer medication was selling drugs brought from abroad that were not authorized by the FDA.
An undercover officer asked to buy Ozempic from this women over TikTok and sent her a $375 payment to a Zelle account and without having a prescription she received a package containing the product labeled Ozempic. The officer said that the unlawful dispensing of the product caused significant life threatening injury’s. The lady was later sent to prison.
- I think that this is very scary and really shows how badly people want this drug but don’t want to spend the cost.

# data[].attributes.attachment_link.title
Woman Who Sold Misbranded Ozempic on TikTok Faces Smuggling Charge

# data[].attributes.attachment_link.description
Federal prosecutors said the woman from Shirley, N.Y., was not licensed to administer medication and was selling drugs brought from abroad that were not authorized by the Food and Drug Administration.

# data[].attributes.attachment_caption
Ozempic subcutaneous: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD

# data[].attributes.attachment_link.title
Ozempic subcutaneous: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD

# data[].attributes.attachment_link.description
Find patient medical information for Ozempic subcutaneous on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

# data[].attributes.attachment_caption
Novo Nordisk announces $6B investment in Ozempic, Wegovy amid shortages

# data[].attributes.attachment_link.readable_text
An executive for Novo Nordisk, the maker of popular drugs used for weight loss including Ozempic and Wegovy, says the company is investing over $6 billion dollars to help meet the increased demand for the drugs amid ongoing shortages and high prices.

Negelle Morris, senior vice president and head of U.S. cardiometabolic sales at Novo Nordisk Inc., warned though that even with the increased investment, there will still likely be a delay in getting the drugs to the market.

"It's not like a light switch," Morris told ABC News' Erielle Reshef in an exclusive interview that aired Thursday on " Good Morning America." "The strategy is to be very mindful and thoughtful about the amount of the lower doses that we're putting into the market, and I think that over time, the investments that we're making in manufacturing capabilities will ensure that over time we're able to meet that demand."

The three smallest doses for Wegovy, ranging from 0.25 milligram to 1 milligram, currently have "limited availability," according to the U.S. Food and Drug Administration.

Novo Nordisk told ABC News that despite the shortages for Wegovy, the company has enough product on the market to start 25,000 patients on Wegovy per week -- a fourfold increase since late last year.

In addition, Novo Nordisk has agreed to acquire three production facilities from pharma and biotech company Catalent for $11 billion, and the company expects to complete the acquisition by the end of the year.

Ozempic is currently available in all dosages, according to the FDA, but has experienced shortages over the past two years as demand for drugs used for weight loss has continued to skyrocket.

The anti-diabetic medication Ozempic is pictured in a pharmacy on April 13, 2023.

Florian Gaertner/Photothek via Getty Images

Ozempic is approved by the U.S. Food and Drug Administration to treat Type 2 diabetes, but some doctors prescribe the medication "off-label" for weight loss, as is permissible by the FDA.

Wegovy, a medication that contains the same main ingredient, semaglutide, as Ozempic, is FDA-approved for weight loss.

Along with physical access to the medications, financial access has also been a barrier for people with diabetes and obesity who might benefit from the drugs.

Without insurance coverage, the out-of-pocket cost for medications like Ozempic and Wegovy can run as high as $1,000 or more per month.

Last month, a U.S. Senate committee led by Sen. Bernie Sanders of Vermont launched an investigation into the high cost of the two medications.

Novo Nordisk told ABC News the company is working with insurance companies to lower the cost of the drugs, as well as with lawmakers to have the drugs covered by Medicare for obesity.

Morris said Novo Nordisk agrees that the medications "need to be more affordable" but did not offer further specifics.

Negelle Morris, senior vice president of Novo Nordisk, speaks out on "Good Morning America" about drugs used for weight loss.

"I can absolutely assure America that we're doing everything that we can, not only to reduce cost and out of pocket in a way that is consistent with the health care system that we have in the U.S., but also to increase supply," Morris said. "Our manufacturing facilities are working 24/7."

She continued, "The plan that we had to be thoughtful and certainly responsible, but also to increase access to this medication by releasing more of those lower doses, allowing more new patients to start, is something that we'll continue to work on."

When asked by Reshef where the profit from the sales of Wegovy and Ozempic is directed, Morris said it goes back into research and innovation for new medicines and a unit dedicated to preventing obesity.

# data[].attributes.attachment_link.title
Novo Nordisk announces $6B investment in Ozempic, Wegovy amid shortages

# data[].attributes.attachment_link.description
Negelle Morris, Novo Nordisk's senior vice president and head of U.S. cardiometabolic sales, spoke exclusively with ABC News.